Compare AbbVie Inc (ABBV) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ProShares Ultra QQQ ETF — how do they compare? AbbVie Inc trades at $249.56 (market cap $438.19B), while ProShares Ultra QQQ ETF trades at $92.14. The key difference: AbbVie Inc pays a 2.79% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals.
| ABBV | QLD | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $263.58 | $100.53 |
52-Week Low | $197.38 | $57.16 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
QLD, the ProShares Ultra QQQ ETF, trades at $92.2, up 2.3% today, reflecting strong bullish momentum. Technical indicators show a bullish moving average consensus and key support at $91, with resistance at $93. Recent institutional buying, including a 29.4% stake increase by 180 Wealth Advisors in Q2 2026, underscores confidence. The ETF has delivered over 10,000% total return since inception, though its leveraged structure amplifies volatility.
The outlook for QLD is cautiously optimistic, driven by tech sector strength and tactical ETF demand. However, risks include amplified losses during market downturns, with a historical maximum drawdown of 63.80%. Investors should weigh the potential for outsized gains against the inherent volatility of daily leveraged products in a shifting economic landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
